VBLT News and Press, Vascular Biogenics Ltd. From 03/25/21

Conference Call and Webcast at 8:30 a . m . EDT Today Continued progress in OVAL Phase 3 registration enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer; high CA-125 response rates (RR)...

TEL AVIV, Israel, March 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its fourth quarter and full year results for the period ended December 31, 2020 on Thursday, March 25, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron,...

The following slide deck was published by Vascular Biogenics Ltd. in conjunction with this event. For further details see: Vascular Biogenics (VBLT) Investor Presentation - Slideshow

TEL AVIV, Israel, March 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the Company will participate in the following upcoming virtual investor conferences: H.C Wainwright Global Life Sciences Conference Tuesday, March 9, 2021 Presentation availabl...

VBL Therapeutics (VBLT) shares jump 7% premarket after announcing the online publication of positive results of the pre-specified interim analysis of the OVAL study, a Phase 3 registration enabling study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian...

Analysis show s a CA-125 response of at least 58% in the VB-111 treatment arm Published online in Gynecologic Oncology TEL AVIV, Israel, March 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the online publicat...

While doing some speculative biotech window shopping, I came across VBL Therapeutics sitting on the sub-$100M market cap shelf. After a quick inspection, I am heading to the checkout. The company's lead candidate, VB-111, is moving closer to the finish line in platinum-resistant ovari...

Investigator-sponsored study will be conducted at seven centers in the U.S. TEL AVIV, Israel, March 01, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec (VB-...

Gainers: Yunhong CTI (CTIB) +51%.TimkenSteel (TMST) +42%.Frank's International (FI) +33%.Sunesis Pharmaceuticals (SNSS) +22%.EverQuote (EVER) +14%.China Southern Airlines (ZNH) +14%.The L.S. Starrett (SCX) +14%.Centrais Eletricas Brasileiras (EBR) +11%.Ardagh Group (ARD) +11%.Vascul...

Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed (PAVM) -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics (ONTX) -15%, elect...